SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.38-2.5%11:25 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (16506)12/3/2003 8:41:34 PM
From: Cacaito  Read Replies (2) of 17367
 
Are they alive! do they keep Weiss et al, in bpi infusion !

No wonder, they rescue wreckage, well there is one more that need rescue from lack of earnings in 2004!

Well, maybe xoma could pitch in and bring down to 20% what Lilly brought down from 31%!

More seriously, I ask both of you (that means blue, rkk and gw) to check on Chiron's Tifacogin phase III results, after oustanding phase II (which should be check too) and the accompaning editorial. Very messy, heparin seems to have very powerful effect, therefore any sepsis trial that does not control for heparin is bound to mess. Giroir should check for heparin use during xoma meningococcemia trial, it could bring interesting data. Now, Steroids have been clearly shown to decrease mortality in a very good phase III, also strict control of sugar levels with insulin was proven to decrease mortality, and stop using pulmonary wedge catheters, and control (or stop) the use of albumin, and good use of central venous pressure.

Once xoma controls for all of that, then they could embark on the real trial: bpi for ACNE !!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext